-
[show abstract]
[hide abstract]
ABSTRACT: Bladder cancer is the fifth most common malignancy in the Western world and the second most frequently diagnosed genitourinary tumor. In the majority of cases, death from bladder cancer results from metastatic disease. Understanding the multistep process of carcinogenesis and metastasis in urothelial cancers is pivotal to the development of new therapeutic strategies. Molecular imaging of cancer growth and metastasis in preclinical models provides the essential link between cell-based experiments and clinical translation.
Develop preclinical models for sensitive bladder cancer cell tracking during tumor progression and metastasis.
A human transitional cell carcinoma UM-UC-3 cell line was generated that stably expresses luciferase 2 (UM-UC-3luc2), a mammalian codon-optimized firefly luciferase with superior expression. Preclinical models were developed with human UM-UC-3luc2 cells xenografted into the bladder (orthotopic model with metastases) or inoculated into the left cardiac ventricle (bone metastasis model) of immunocompromised mice.
Noninvasive, sensitive bioluminescent imaging of human firefly luciferase 2-positive bladder cancer in mice using the IVIS100 imaging system.
In the orthotopic model (intravesical inoculation), tumor growth could be followed directly after inoculation of UM-UC-3luc2 cells. Importantly, micrometastatic lesions originating from orthotopically implanted cancer cells could be detected in the locoregional lymph nodes and in distant organs. In addition, the superior bioluminescent indicator firefly luciferase 2 allows the detection and monitoring of micrometastatic lesions in real time after intracardiac inoculation of human bladder cancer cells in mice. The main disadvantage is the lack of T-cell immunity in the preclinical models.
The new bioluminescence-based preclinical bladder cancer models enable superior, noninvasive, and real-time tracking of cancer cells, tumor progression, and micrometastasis. Because of the significant improvement in detection of small cell numbers, the presented models are ideally suited for functional studies dealing with minimal residual disease as well as real-time imaging of drug response.
European urology 08/2011; 60(2):337-43. · 7.67 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Bladder perforation is a complication which can occur after a Prolift procedure and may enhance vesicovaginal fistula formation. Different methods of management of bladder perforation caused by mesh procedures are described in the literature, and most authors advise complete excision of the mesh. In the case described in this article, we propose a combined transurethral and suprapubical approach as the optimal method for maximal tape removal, being both minimally invasive and less damaging to the vesical wall. A suprapubical catheter can be removed shortly after surgery to enable optimal tissue healing of the vesical mucosa.
International Urogynecology Journal 03/2010; 21(10):1301-3. · 1.83 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Urothelial carcinoma of the bladder is diagnosed predominantly in people over 60 years of age. The most common symptom is haematuria. Smoking is an important risk factor (relative risk 2.5 to 3). Cystoscopy is performed whenever bladder carcinoma is suspected. The recurrence rate of a non-muscle invasive urothelial carcinoma is high (31-78% within 5 years). A single intravesical instillation with a chemotherapeutic agent within 24 hours of transurethral resection (TUR) reduces the risk of recurrence. Carcinoma in situ (CIS) should be treated as high-grade urothelial carcinoma. Standard treatment for patients with non-metastasized muscle-invasive urothelial carcinoma is cystectomy in combination with extensive lymph node dissection. There are several possibilities for urinary diversion following cystectomy, none of which are any better than the others. Bladder-sparing brachytherapy may be used in patients with solitary T1 - T2 urothelial carcinoma < 5 cm. Neoadjuvant cisplatin-containing chemotherapy prior to cystectomy in muscle-invasive carcinoma only slightly improves survival. Cisplatin-containing combination chemotherapy is the standard treatment for metastasized urothelial carcinoma.
Nederlands tijdschrift voor geneeskunde 01/2009; 153:A956.
-
[show abstract]
[hide abstract]
ABSTRACT: To assess the status of urologic laparoscopy in the Netherlands in 2005.
A personal e-mail survey was sent to all practicing Dutch urologists to assess the urologic laparoscopic practice patterns in the Netherlands in 2005.
Data were gathered from 86.8% of all urologists receiving the survey. In 2005, 25.5% of Dutch urologists performed laparoscopic procedures. The median number of laparoscopic procedures per urologist was low: 23 per year. Of all non-laparoscopists, 28.5% indicated an intent to begin performing laparoscopic procedures within 1 year.
All currently performed laparoscopic urologic procedures were performed in the Netherlands in 2005, but the number of such procedures performed per year is low.
Journal of Endourology 06/2008; 22(5):969-72. · 1.85 Impact Factor
-
European Radiology 02/2006; 16(1):240-1. · 3.22 Impact Factor
